Piro Lito: Featured News

Share
Print
Share
Print
Finding
Yonina Murciano-Goroff, Jenny Xue, Bob Li, Piro Lito, and Yulei Zhao.
MSK Researchers Are Learning Why Some Patients Develop Resistance to ‘Landmark’ Lung Cancer Drug
The recent approval of sotorasib (LumakrasTM) was considered a watershed event, because the drug obstructs a cancer-causing protein that for decades sc...
In the Lab
Physician-scientist Piro Lito
Researchers Uncover New Findings about KRAS, an Important Protein in Cancer
One of the most exciting advances in cancer treatment over the past few years has been the development of the drug sotorasib (LumakrasTM) for treating ...
Feature
Three photos of Karen Milich: one with her grandson, one of her with her sons, and one of her alone
How Four Decades of Research Led to a Breakthrough Treatment for Lung Cancer
Update: On May 28, 2021, the US Food and Drug Administration approved sotorasib (LumakrasTM) for the treatment of advanced non-small cell lung cancer d...
In the Clinic
Piro Lito, Bob Li, and Neal Rosen in the lab
Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease con...
In the Lab
Physician-scientist Piro Lito
Why KRAS Inhibitors for Lung Cancer Stop Working (and What Can Be Done about It)
Summary Scientists at Memorial Sloan Kettering have discovered why certain drugs used to treat lung cancer are only partially effective. The findi...
In the Lab
Representative image of a dividing tumor cell showing the extrachromosomal location of duplicated BRAF genes
Giving Drugs Together — Rather than in Sequence — May Be Key to Halting Tumor Resistance
Summary Drugs targeting a particular mutation in cancer cells can be an effective form of therapy. But the beneficial effects are often short-live...
In the Lab
Colored x-ray of lung cancer
New Lung Cancer Therapy May Target Previously Untreatable Tumors
Summary Although some lung cancer patients have benefited from developments in precision therapy, those with mutations in a gene called KRAS have ...